Evidence map›Paper›PMID 24349248›Full record

ArticlePloS one2013

The prevention of diabetic cardiomyopathy by non-mitogenic acidic fibroblast growth factor is probably mediated by the suppression of oxidative stress and damage.

Chi Zhang, Linbo Zhang, Shali Chen, Biao Feng, Xuemian Lu, Yang Bai, Guang Liang, Yi Tan, Minglong Shao, Melissa Skibba and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 54 citations in OpenAlex.

  1. Human FGF1Cells · 2026
    Article
  2. Article
  3. Article
  4. Resveratrol as a cardioprotective adjuvant for 5-fluorouracil in the treatment of gastric cancer cells.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Emerging Theranostic Nanomaterials in Diabetes and Its Complications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Chi ZhangChinese-American Research Institute for Diabetic Complications, Wenzhou Medical University, Wenzhou, Zhejiang, China ; Ruian Center of the Chinese-American Research Institute for Diabetic Complications, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Linbo ZhangDepartment of Pathology, Western University, London, Ontario, Canada ; Department of Pharmaceutical Engineering, Jilin Agriculture University, Changchun, Jilin, China.
Shali ChenDepartment of Pathology, Western University, London, Ontario, Canada.
Biao FengDepartment of Pathology, Western University, London, Ontario, Canada.
Xuemian LuRuian Center of the Chinese-American Research Institute for Diabetic Complications, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yang BaiDepartment of Cardiac Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Guang LiangChinese-American Research Institute for Diabetic Complications, Wenzhou Medical University, Wenzhou, Zhejiang, China ; School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yi TanChinese-American Research Institute for Diabetic Complications, Wenzhou Medical University, Wenzhou, Zhejiang, China ; Departments of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, United States of America ; Kosair Children's Hospital Research Institute, Department of Pediatrics, University of Louisville, Louisville, Kentucky, United States of America.
Minglong ShaoChinese-American Research Institute for Diabetic Complications, Wenzhou Medical University, Wenzhou, Zhejiang, China ; Ruian Center of the Chinese-American Research Institute for Diabetic Complications, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Melissa SkibbaDepartments of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, United States of America.
Litai JinChinese-American Research Institute for Diabetic Complications, Wenzhou Medical University, Wenzhou, Zhejiang, China ; School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiaokun LiChinese-American Research Institute for Diabetic Complications, Wenzhou Medical University, Wenzhou, Zhejiang, China ; Department of Cardiac Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Subrata ChakrabartiDepartment of Pathology, Western University, London, Ontario, Canada.
Lu CaiChinese-American Research Institute for Diabetic Complications, Wenzhou Medical University, Wenzhou, Zhejiang, China ; Departments of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, United States of America ; Kosair Children's Hospital Research Institute, Department of Pediatrics, University of Louisville, Louisville, Kentucky, United States of America.
Western University · CAUniversity of Louisville · USWenzhou Medical University · CNFirst Hospital of Jilin University · CNRuian People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmerging evidence showed the beneficial effect of acidic fibroblast growth factor (aFGF) on heart diseases. The present study investigated whether non-mitogenic aFGF (nm-aFGF) can prevent diabetic cardiomyopathy and the underlying mechanisms, if any. METHODOLOGY/PRINCIPAL

findingsType 1 diabetes was induced in mice by multiple intraperitoneal injections of low-dose streptozotocin. Hyperglycemic and age-matched control mice were treated with or without nm-aFGF at 10 µg/kg daily for 1 and 6 months. Blood pressure and cardiac function were assessed. Cardiac H9c2 cell, human microvascular endothelial cells, and rat cardiomyocytes were exposed to high glucose (25 mM) for mimicking an in vitro diabetic condition for mechanistic studies. Oxidative stress, DNA damage, cardiac hypertrophy and fibrosis were assessed by real-time qPCR, immunofluorescent staining, Western blotting, and pathological examination. Nm-aFGF significantly prevented diabetes-induced hypertension and cardiac dysfunction at 6 months. Mechanistic studies demonstrated that nm-aFGF showed the similar preventive effect as the native aFGF on high glucose-induced oxidative stress (increase generation of reactive oxygen species) and damage (cellular DNA oxidation), cell hypertrophy, and fibrotic response (increased mRNA expression of fibronectin) in three kinds of cells. These in vitro findings were recaptured by examining the heart of the diabetic mice with and without nm-aFGF.

conclusionsThese results suggest that nm-aFGF can prevent diabetic cardiomyopathy, probably through attenuation of cardiac oxidative stress, hypertrophy, and fibrosis.

Indexed as

DNA DamageOxidative StressAnimalsBlood GlucoseBlood PressureBody WeightCardiomegalyCell LineDiabetic CardiomyopathiesFibroblast Growth Factor 1FibrosisGene Expression RegulationHeart RateHumansMaleMiceBlood GlucoseFibroblast Growth Factor 1MitogensRNA, Messenger

Identifiers

PMID24349248
PMCPMC3857250
OpenAlexW2044827904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.